Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.02
TEVJF's Cash-to-Debt is ranked lower than
98% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. TEVJF: 0.02 )
Ranked among companies with meaningful Cash-to-Debt only.
TEVJF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.22 Max: 1.03
Current: 0.02
0.02
1.03
Equity-to-Asset 0.33
TEVJF's Equity-to-Asset is ranked lower than
87% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. TEVJF: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
TEVJF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.49 Max: 0.6
Current: 0.33
0.32
0.6
Debt-to-Equity 1.21
TEVJF's Debt-to-Equity is ranked lower than
88% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. TEVJF: 1.21 )
Ranked among companies with meaningful Debt-to-Equity only.
TEVJF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.27  Med: 0.57 Max: 1.25
Current: 1.21
0.27
1.25
Debt-to-EBITDA -10.00
TEVJF's Debt-to-EBITDA is ranked lower than
99.99% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. TEVJF: -10.00 )
Ranked among companies with meaningful Debt-to-EBITDA only.
TEVJF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.43  Med: 2.97 Max: 12.37
Current: -10
1.43
12.37
Piotroski F-Score: 4
Altman Z-Score: 0.32
Beneish M-Score: -2.95
WACC vs ROIC
2.70%
-4.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -19.66
TEVJF's Operating Margin % is ranked lower than
79% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. TEVJF: -19.66 )
Ranked among companies with meaningful Operating Margin % only.
TEVJF' s Operating Margin % Range Over the Past 10 Years
Min: 8.12  Med: 17.02 Max: 25.46
Current: -19.66
8.12
25.46
Net Margin % -24.35
TEVJF's Net Margin % is ranked lower than
80% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. TEVJF: -24.35 )
Ranked among companies with meaningful Net Margin % only.
TEVJF' s Net Margin % Range Over the Past 10 Years
Min: 1.5  Med: 12.03 Max: 20.75
Current: -24.35
1.5
20.75
ROE % -18.73
TEVJF's ROE % is ranked lower than
79% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. TEVJF: -18.73 )
Ranked among companies with meaningful ROE % only.
TEVJF' s ROE % Range Over the Past 10 Years
Min: 0.22  Med: 10 Max: 16.18
Current: -18.73
0.22
16.18
ROA % -6.26
TEVJF's ROA % is ranked lower than
75% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. TEVJF: -6.26 )
Ranked among companies with meaningful ROA % only.
TEVJF' s ROA % Range Over the Past 10 Years
Min: 0.45  Med: 4.98 Max: 9.34
Current: -6.26
0.45
9.34
ROC (Joel Greenblatt) % -62.74
TEVJF's ROC (Joel Greenblatt) % is ranked lower than
80% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. TEVJF: -62.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TEVJF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.82  Med: 33.66 Max: 49.49
Current: -62.74
16.82
49.49
3-Year Revenue Growth Rate -1.60
TEVJF's 3-Year Revenue Growth Rate is ranked lower than
73% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. TEVJF: -1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TEVJF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 14.9 Max: 37.4
Current: -1.6
-1.6
37.4
3-Year EBITDA Growth Rate -8.00
TEVJF's 3-Year EBITDA Growth Rate is ranked lower than
79% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. TEVJF: -8.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TEVJF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -9.6  Med: 16.3 Max: 47.4
Current: -8
-9.6
47.4
3-Year EPS without NRI Growth Rate -63.90
TEVJF's 3-Year EPS without NRI Growth Rate is ranked lower than
98% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. TEVJF: -63.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TEVJF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -63.9  Med: 16 Max: 119.7
Current: -63.9
-63.9
119.7
GuruFocus has detected 3 Warning Signs with Teva Pharmaceutical Industries Ltd TEVJF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TEVJF's 30-Y Financials

Financials (Next Earnings Date: 2018-02-13)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with TEVJF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF284.3724.627 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:TSE:4508, SHSE:600196, OCSE:LUN, NYSE:PRGO, SHSE:600518, TSE:4523, SZSE:000538, JSE:APN, XPAR:IPN, TSE:4507, XSWX:VIFN, SZSE:000963, BOM:532321, HKSE:03320, SHSE:603858, SHSE:600332, SHSE:600085, NSE:SUNPHARMA, BOM:500257, SZSE:300122 » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVA.USA,
Headquarter Location:Israel
Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces and markets generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines.

Headquartered in Israel, Teva Pharmaceutical is the world's largest generic pharmaceutical manufacturer. The company also develops and sells branded pharmaceuticals in central nervous system, oncology, respiratory, and women's health categories. After acquiring Allergan's generics business, Teva's generic sales should be over 60% of total revenue, with branded drug and international over-the-counter revenue making up the balance of sales. Copaxone makes up about half of Teva's branded drug segment, with about $4 billion in sales for 2015.

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

Wall Street Bearish Ahead of Bank of England's Interest Rate Hike Teva falls on disappointing quarterly results
The U.S. stock market was mostly lower in Thursday premarket trading after the Bank of England increased its interest rate for the first time in a decade. The rate rose to 0.5% from 0.25%. Further, the U.S. dollar fell against other major currencies after more details regarding the Republican tax plan were released. Read more...
Bernard Horn Comments on Teva Pharmaceutical Guru stock highlight
Teva Pharmaceutical (NYSE:TEVA), the Israeli drug company, dropped materially during the quarter. The company faced a perfect storm of industry pressures and self-inflicted missteps. Pricing pressure in the U.S. generics market was worse than normal. The resultant lower cash flow, and a high debt load from the Allergan acquisition, forced the company to cut its dividend and warn that debt covenants may be violated. Management planned asset sales to help alleviate cash requirements. Generic drug competition also impacted Allergan, as the stock declined nearly 15% on concerns of a 2018 generic alternative to Allergan’s flagship Alzheimer’s drug, Namenda. However, Allergan’s current drug portfolio remains resilient, led by advances in Botox and the introduction of Namzaric. Company management also signaled its intention to add new medicines and expand via acquisitions. Read more...
INVESTOR ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited
TEVA PHARMACEUTICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Limited - (TEV
Stocks That Fell to 3-Year Lows in the Week of Oct. 6 BT Group PLC (BT), Cardinal Health Inc. (CAH), Teva Pharmaceutical Industries Ltd (TEVA), and Chipotle Mexican Grill Inc. (CMG) have declined to their respective three-year lows.
BT Group PLC (NYSE:BT), Cardinal Health Inc. (NYSE:CAH), Teva Pharmaceutical Industries Ltd (NYSE:TEVA), and Chipotle Mexican Grill Inc. (NYSE:CMG) have declined to their three-year lows. Read more...
Mylan Rises on FDA Approval of Generic MS Drug Teva falls as Copaxone now has competition
The S&P 500, Nasdaq and Dow Jones opened lower on Wednesday after registering record highs the past several days, but soon reversed. Read more...
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm
The Klein Law Firm Reminds Investors of Commencement of a Class Action Commenced on Behalf of Teva Pharmaceutical Industries Ltd. Shareholders and a Lead Plaintiff Deadline of October 23, 2017 (TEVA)
APPROACHING DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Teva Pharmaceutical Industries Limited (NYSE: TEVA) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

Ratios

vs
industry
vs
history
Forward PE Ratio 5.03
TEVJF's Forward PE Ratio is ranked higher than
93% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. TEVJF: 5.03 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 0.56
TEVJF's PB Ratio is ranked higher than
93% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. TEVJF: 0.56 )
Ranked among companies with meaningful PB Ratio only.
TEVJF' s PB Ratio Range Over the Past 10 Years
Min: 0.46  Med: 2.04 Max: 2.91
Current: 0.56
0.46
2.91
PS Ratio 0.60
TEVJF's PS Ratio is ranked higher than
87% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. TEVJF: 0.60 )
Ranked among companies with meaningful PS Ratio only.
TEVJF' s PS Ratio Range Over the Past 10 Years
Min: 0.5  Med: 2.55 Max: 4.33
Current: 0.6
0.5
4.33
Price-to-Free-Cash-Flow 5.00
TEVJF's Price-to-Free-Cash-Flow is ranked higher than
93% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. TEVJF: 5.00 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TEVJF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.12  Med: 13.24 Max: 32.03
Current: 5
4.12
32.03
Price-to-Operating-Cash-Flow 3.75
TEVJF's Price-to-Operating-Cash-Flow is ranked higher than
94% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. TEVJF: 3.75 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TEVJF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.09  Med: 10.25 Max: 22.47
Current: 3.75
3.09
22.47
EV-to-EBIT -9.64
TEVJF's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. TEVJF: -9.64 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVJF' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.7  Med: 19.9 Max: 192.9
Current: -9.64
-14.7
192.9
EV-to-EBITDA -14.96
TEVJF's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. TEVJF: -14.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVJF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.2  Med: 13.9 Max: 39.1
Current: -14.96
-24.2
39.1
EV-to-Revenue 2.22
TEVJF's EV-to-Revenue is ranked higher than
59% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. TEVJF: 2.22 )
Ranked among companies with meaningful EV-to-Revenue only.
TEVJF' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 3.1 Max: 4.6
Current: 2.22
2.1
4.6
Shiller PE Ratio 8.38
TEVJF's Shiller PE Ratio is ranked higher than
93% of the 204 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.18 vs. TEVJF: 8.38 )
Ranked among companies with meaningful Shiller PE Ratio only.
TEVJF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 6.91  Med: 25.75 Max: 58.92
Current: 8.38
6.91
58.92
Current Ratio 0.96
TEVJF's Current Ratio is ranked lower than
91% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. TEVJF: 0.96 )
Ranked among companies with meaningful Current Ratio only.
TEVJF' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.57 Max: 2.95
Current: 0.96
0.9
2.95
Quick Ratio 0.66
TEVJF's Quick Ratio is ranked lower than
92% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. TEVJF: 0.66 )
Ranked among companies with meaningful Quick Ratio only.
TEVJF' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.02 Max: 2.19
Current: 0.66
0.61
2.19
Days Inventory 158.46
TEVJF's Days Inventory is ranked lower than
68% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. TEVJF: 158.46 )
Ranked among companies with meaningful Days Inventory only.
TEVJF' s Days Inventory Range Over the Past 10 Years
Min: 162.08  Med: 186.4 Max: 208.14
Current: 158.46
162.08
208.14
Days Sales Outstanding 115.71
TEVJF's Days Sales Outstanding is ranked lower than
76% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. TEVJF: 115.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVJF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 115.71
95.91
153.21
Days Payable 73.65
TEVJF's Days Payable is ranked higher than
52% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. TEVJF: 73.65 )
Ranked among companies with meaningful Days Payable only.
TEVJF' s Days Payable Range Over the Past 10 Years
Min: 78.39  Med: 84.39 Max: 111.41
Current: 73.65
78.39
111.41

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.56
TEVJF's Dividend Yield % is ranked higher than
98% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. TEVJF: 4.56 )
Ranked among companies with meaningful Dividend Yield % only.
TEVJF' s Dividend Yield % Range Over the Past 10 Years
Min: 0.66  Med: 2.13 Max: 9.69
Current: 4.56
0.66
9.69
3-Year Dividend Growth Rate 2.00
TEVJF's 3-Year Dividend Growth Rate is ranked lower than
62% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. TEVJF: 2.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TEVJF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -6.7  Med: 23.6 Max: 80.9
Current: 2
-6.7
80.9
Forward Dividend Yield % 9.13
TEVJF's Forward Dividend Yield % is ranked higher than
98% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.05 vs. TEVJF: 9.13 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 7.02
TEVJF's 5-Year Yield-on-Cost % is ranked higher than
96% of the 849 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. TEVJF: 7.02 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TEVJF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.02  Med: 3.28 Max: 14.91
Current: 7.02
1.02
14.91
3-Year Average Share Buyback Ratio -2.30
TEVJF's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. TEVJF: -2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEVJF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.6  Med: -2.3 Max: 4.6
Current: -2.3
-12.6
4.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.24
TEVJF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
96% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. TEVJF: 0.24 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TEVJF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.31  Med: 1.56 Max: 11.3
Current: 0.24
0.31
11.3
Price-to-Median-PS-Value 0.24
TEVJF's Price-to-Median-PS-Value is ranked higher than
95% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. TEVJF: 0.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TEVJF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.07 Max: 2.28
Current: 0.24
0.3
2.28
Earnings Yield (Greenblatt) % -10.37
TEVJF's Earnings Yield (Greenblatt) % is ranked lower than
83% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. TEVJF: -10.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TEVJF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -10.6  Med: 4.8 Max: 8.8
Current: -10.37
-10.6
8.8
Forward Rate of Return (Yacktman) % 24.11
TEVJF's Forward Rate of Return (Yacktman) % is ranked higher than
64% of the 397 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.07 vs. TEVJF: 24.11 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TEVJF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2  Med: 22.8 Max: 45.5
Current: 24.11
-2
45.5

More Statistics

Revenue (TTM) (Mil) $23,418.00
EPS (TTM) $ -5.96
Beta-0.67
Short Percentage of Float0.00%
52-Week Range $14.50 - 51.06
Shares Outstanding (Mil)1,016.00

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 22,251 20,472 20,841 21,195
EPS ($) 3.90 2.96 2.81 2.97
EPS without NRI ($) 3.90 2.96 2.81 2.97
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-5.64%
Dividends per Share ($) 0.60 0.36 0.41 0.45

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}